WC
IBER.U

Wealthspring Capital’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Wealthspring Capital’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,040
Closed -$180K – 202
2022
Q4 		$180K Sell
18,040
-177,162
-91% -$1.77M 0.27% 129
2022
Q3 		$1.93M Sell
195,202
-5,210
-3% -$51.6K 0.38% 67
2022
Q2 		$1.96M Sell
200,412
-10,540
-5% -$104K 0.37% 60
2022
Q1 		$2.07M Sell
210,952
-20,230
-9% -$201K 0.41% 54
2021
Q4 		$2.32M Sell
231,182
-19,320
-8% -$193K 0.5% 43
2021
Q3 		$2.5M Sell
250,502
-26,690
-10% -$266K 0.6% 37
2021
Q2 		$2.79M Sell
277,192
-16,248
-6% -$163K 0.7% 29
2021
Q1 		$2.89M Buy
+293,440
New +$2.93M 0.78% 31

Wealthspring Capital's IBER.U Position: Q1 2023 in Review

Wealthspring Capital sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 18,040 shares — an estimated $180K sold.

Wealthspring Capital first reported a position in IBER.U in Q1 2021 and held it in 8 quarters. The position peaked at $2.89M in Q1 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • Wealthspring Capital reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
  • Wealthspring Capital sold 18,040 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $180K.
  • Wealthspring Capital first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 8 quarters.
  • Wealthspring Capital's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $2.89M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on Wealthspring Capital's 13F filing for Q1 2023, filed 25 Apr 2023.